about
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisThe structural basis of bone fragility in men.Vertebral bone mass, size, and volumetric density in women with spinal fractures.Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians.Diet and exercise during growth have site-specific skeletal effects: a co-twin control study.Construction of the femoral neck during growth determines its strength in old age.Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes.Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronateDiagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.Selection of individuals for prevention of fractures due to bone fragility.Pathogenesis of bone fragility in women and men.Cortical porosity identifies women with osteopenia at increased risk for forearm fractures.Unresolved issues in osteoporosis in men.During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone.The structural and biomechanical basis of the gain and loss of bone strength in women and men.Fracture rates lower in rural than urban communities: the Geelong Osteoporosis StudyMicroarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS).Osteoporosis and the global competition for health care resources.Osteoporosis in men--consensus is premature.Relationships among liver and kidney volumes, lean body mass and drug clearance.Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures.Loading and bone fragility.Bone quality--the material and structural basis of bone strength and fragility.Bone fragility in men--where are we?Towards a diagnostic and therapeutic consensus in male osteoporosisThe periosteum--a surface for all seasons.Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.Non-compliance: the Achilles' heel of anti-fracture efficacy.Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudyBone quality: the material and structural basis of bone strength.Common variants in the region around Osterix are associated with bone mineral density and growth in childhoodSkeletal growth and peak bone strength.Bone remodelling: its local regulation and the emergence of bone fragility.Evidence that calcium supplements reduce fracture risk is lacking.Epidemiology and structural basis of racial differences in fragility fractures in Chinese and Caucasians.High-resolution in vivo imaging of bone and joints: a window to microarchitecture.
P50
Q28241336-D7F64EB8-1414-4958-A2B4-A90537C36DF4Q30743833-A43FEDA8-7D86-4EF7-AA45-475B24528B23Q30775011-4AAAC19E-F25B-4C62-BA9A-1B3F7F492461Q30783235-106A7510-4927-473C-80B9-F094FA2E1E84Q31155090-A0F89554-C87C-49CF-815F-A40EA24C45AAQ33284564-1C2F2085-8A96-4B59-8095-46C2A4593B76Q33306121-6EBD08E3-23BA-40A5-AE11-ECEE8D774634Q33587793-286EF8EA-45DB-490B-8A7A-8A7F23296A67Q33707143-78A81AB2-94FA-4274-9E5F-21DC5D7B3744Q33985248-03566E2E-7AF2-4715-B961-84D5EC3CBBBEQ34020652-C4DED2CE-3477-4792-9F83-95AE4EB23B1CQ34063015-B1469F2D-0735-459C-BD01-44B8EB89625DQ34131375-40422173-933C-49CE-9272-AF87D3D4D927Q34145022-7184AB61-B5D7-4736-85A8-FDB2DE34E328Q34435641-2C939C46-9012-45C2-8BCF-3921208885F0Q34454739-25B36473-814B-4CF7-B624-01CAB7F2CEA9Q35108965-2A38C317-F823-4BE7-AA56-4D041FDDFE93Q35408382-A6C067D1-C3F4-4EC8-AA4F-708573F45B42Q35653722-9D9FEA22-34CA-4D89-857E-8C7B4584789AQ35746410-626727D0-3526-48CE-B4A5-714A1C0C03A9Q35791817-A3A33C3B-7854-42D1-84FE-2E9EB66B404FQ35797221-DFEF3900-D746-4D4E-8D4F-E97763EDFEBBQ35802646-7067E837-382C-4D5E-90FB-30291EA942EEQ35856095-18E92833-CF84-4A88-A6E3-CABF4820FAF6Q36177511-00D476EB-F7C3-4850-9AB9-1767D7299539Q36488553-073C3B1B-14BE-40FA-A099-228F1C8785D5Q36560251-8BF60705-44E2-451B-9B44-2B49E5C164A0Q36564415-081CACD0-1BDB-4EF3-A49A-A5503A437473Q36688600-C1EB320E-EB15-4248-9FD8-A580D5F943DAQ36697904-D8C14674-543E-4C77-8DB0-CA54759DF513Q36716496-0BA50B24-9A92-4B8D-AE33-D54E7AB1FF01Q36888245-A62C7A4F-6D2D-40F9-BB04-ADE9ACDC3775Q36932652-0D4CF315-5C20-444B-A29C-E51A91079C30Q37038529-AAFB0D0D-9392-4878-8121-4422537D8076Q37147155-4099B465-EF6A-42B4-B0C6-B2C7EF29451EQ37333051-312D5ADC-A09F-429F-8D00-659597BB30F8Q37333054-FB2DCC2C-96A1-4B3C-B2E8-07453D82DFC2Q37678708-2F4C3C92-FE3E-4ED5-886D-A600FD0ED794Q37919760-74737F77-AF92-49B5-9BD6-AE406727F559Q38193294-44BBC3E6-76B3-42B5-B807-6F5AAA415763
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ego Seeman
@ast
Ego Seeman
@en
Ego Seeman
@es
Ego Seeman
@sl
type
label
Ego Seeman
@ast
Ego Seeman
@en
Ego Seeman
@es
Ego Seeman
@sl
prefLabel
Ego Seeman
@ast
Ego Seeman
@en
Ego Seeman
@es
Ego Seeman
@sl
P106
P1153
7006225993
P21
P31
P496
0000-0002-9692-048X